Puretech Health company information, Employees & Contact Information

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group Business Wire

PureTech Health: Notice of Half-Yearly Results | PRN_FinancialWrapper | PR Newswire FinancialContent

PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases Business Wire

Poorer IPF quality of life reports in community pulmonary practices vs. ILD centers Healio

PureTech Health: Notice of Results The AI Journal

PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF Business Wire

PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF Yahoo Finance

PureTech Appoints Raju Kucherlapati Chair of the Board FirstWord Pharma

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint Business Wire

PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers Yahoo Finance

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference Yahoo Finance

PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions Business Wire

PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement Business Wire

PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments Business Wire

PureTech to Present at the Morgan Stanley Global Healthcare Conference Business Wire

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial Business Wire

PureTech Health plc Statement Regarding Press Speculation Business Wire

PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round Business Wire

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine Business Wire

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022 Business Wire

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion Business Wire

PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64 Business Wire

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers Business Wire

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 Business Wire

PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy) Business Wire

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies Stock Titan

PureTech Appoints Sharon Barber-Lui to Board of Directors & Audit Committee Business Wire

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABA Business Wire

PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300 Business Wire

PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer Business Wire

PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer Business Wire

PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance Business Wire

Monash University signs licensing deal for novel drug delivery technology Monash University

PureTech Founded Entity Akili Enters Strategic samoaobserver.ws

PureTech Announces Annual Results for Year Ended December 31, 2020 samoaobserver.ws